Quetiapine treatment in pediatric scenarios
| Autor: | Maja Drobnič Radobuljac, Barbara Plemeniti Tololeski |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Risperidone business.industry medicine.drug_class Atypical antipsychotic medicine.disease Extrapyramidal symptoms Schizophrenia mental disorders medicine Quetiapine Delirium Bipolar disorder medicine.symptom business Psychiatry Borderline personality disorder medicine.drug |
| DOI: | 10.1016/b978-0-12-817988-8.00035-x |
| Popis: | In this chapter we discuss quetiapine, its mechanisms of actions in the central nervous system, novel antioxidative activity, especially in neuroinflammatory diseases, and current usage in child and adolescent psychiatry. Quetiapine is an atypical antipsychotic with a multireceptor binding profile (5HT2, D2, 5HT1, 5HT7, H1, M1, α1 …) that is used in the treatment of schizophrenia, bipolar disorder, and many other conditions, especially in adults. It is officially approved for the treatment of schizophrenia and bipolar mania in children and adolescents in the United States. Used off-label, it has been effective in children and adolescents with delirium and organic psychosis and as an add-on treatment in emerging borderline personality disorder, conduct disorder, and sleep disturbances. In vitro studies have shown that it also has antioxidant and antiinflammatory properties, which may be beneficial in neuroinflammatory, neurodevelopmental, and neurodegenerative disorders (e.g., schizophrenia, multiple sclerosis). The risks of extrapyramidal symptoms and prolactin elevation with quetiapine are low, which is a great advantage when compared to some of the other atypical antipsychotics such as risperidone. On the other hand, careful and regular monitoring for side effects, especially metabolic, is necessary and should be more frequent with children and adolescents than adults, due to their greater sensitivity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|